# Evaluation of Testosterone Nasal Gel in Hypogonadal Boys

> **NCT03345797** · PHASE1 · TERMINATED · sponsor: **Acerus Biopharma Inc.** · enrollment: 8 (actual)

## Conditions studied

- Hypogonadism

## Interventions

- **DRUG:** Testosterone Nasal Gel [Natesto]

## Key facts

- **NCT ID:** NCT03345797
- **Lead sponsor:** Acerus Biopharma Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-03-01
- **Primary completion:** 2020-04-11
- **Final completion:** 2022-04-11
- **Target enrollment:** 8 (ACTUAL)
- **Why stopped:** Lack of patients and commercial reasons
- **Last updated:** 2023-10-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03345797

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03345797, "Evaluation of Testosterone Nasal Gel in Hypogonadal Boys". Retrieved via AI Analytics 2026-06-07 from https://api.ai-analytics.org/clinical/NCT03345797. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*